The latest price target for Amylyx Pharmaceuticals (NASDAQ:AMLX) was reported by Guggenheim on June 24, 2025. The analyst firm set a price target for $17.00 expecting AMLX to rise to within 12 months (a possible 169.41% upside). 13 analyst firms have reported ratings in the last year.

The latest analyst rating for Amylyx Pharmaceuticals (NASDAQ:AMLX) was provided by Guggenheim, and Amylyx Pharmaceuticals initiated their buy rating.

The last upgrade for Amylyx Pharmaceuticals Inc happened on May 7, 2025 when Leerink Partners raised their price target to $10. Leerink Partners previously had a market perform for Amylyx Pharmaceuticals Inc.

The last downgrade for Amylyx Pharmaceuticals Inc happened on March 11, 2024 when Goldman Sachs changed their price target from $40 to $4 for Amylyx Pharmaceuticals Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Amylyx Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Amylyx Pharmaceuticals was filed on June 24, 2025 so you should expect the next rating to be made available sometime around June 24, 2026.

While ratings are subjective and will change, the latest Amylyx Pharmaceuticals (AMLX) rating was a initiated with a price target of $0.00 to $17.00. The current price Amylyx Pharmaceuticals (AMLX) is trading at is $6.31, which is within the analyst’s predicted range.